The UK Competition Authority opens investigation into alleged abuse of dominance in the supply of drugs used to treat bipolar disorder (Essential Pharma)

CMA to investigate the supply of bipolar drug* The CMA has opened an investigation into suspected anti-competitive practices in the supply of drugs used to treat bipolar disorder. The Competition and Markets Authority (CMA) will investigate whether the pharmaceutical company Essential Pharma has abused a dominant position in relation to lithium-based

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • United Kingdom’s Competition Authority - CMA (London)

Quotation

UK Competition Authority, The UK Competition Authority opens investigation into alleged abuse of dominance in the supply of drugs used to treat bipolar disorder (Essential Pharma), 6 October 2020, e-Competitions November 2020 - II, Art. N° 97274

Visites 123

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues